Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Chuikyo OKs Listing of 18 Meds, All Get Price Premiums; Biggest Peak Sales for Beyfortus
The Central Social Insurance Medical Council (Chuikyo) on May 15 approved 18 medicines for reimbursement listing later this month, with the largest peak sales projected for AstraZeneca’s Beyfortus (nirsevimab), an anti-respiratory syncytial virus (RSV) antibody. All 18 drugs (APIs)/22 products,…
To read the full story
Related Article
- Astellas’ Gastric Cancer Drug Vyloy Now Available in Japan
June 13, 2024
- Maruho Launches Mitchga 30 mg Vial Version in Japan
June 12, 2024
- Takeda Rolls Out Obizur for Acquired Hemophilia A in Japan
June 11, 2024
- Viatris Launches Cystadrops, Its 1st Brand-Name Product in Japan
May 31, 2024
- Takeda’s cTTP Drug Adzynma Now Available in Japan
May 31, 2024
- AstraZeneca’s Beyfortus, Pfizer’s Elrexfio and More Now Available in Japan
May 23, 2024
- First Innovation Premium in 6 Years Axed for Sargmalin, “Zero” Rule Hits Yet Again
May 16, 2024
- Japan Approves Piasky, Beyfortus, Broader Use for Abrysvo, and Lot More
March 27, 2024
REGULATORY
- MHLW to Allow OTC Drugs to Match Prescription Doses under Specific Conditions
February 5, 2026
- Japan Launches Biotechnology Working Group, Roadmap Draft Due in April
February 4, 2026
- Japan Panel Backs Nonprescription Switch of Second Emergency Contraceptive
February 4, 2026
- MHLW Set to Launch Searchable Drug Supply Database in April
February 3, 2026
- MHLW Pushes Back GCP Ordinance Revision to Summer
February 3, 2026
Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key
Japan is poised to make the most sweeping revision in eight years to the Standards for Biological Raw Materials —…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…